Study finds 65% of Americans with mental health issues want access to psychedelics

A new study by The Harris Poll and Delic Holdings Corp. found that 65% of affected Americans want access to psychedelics for their mental health.

Respondents who reported suffering from a mental health condition say psychedelic medicine, including ketamine, psilocybin mushrooms and MDMA, should be made available to patients with resistant anxiety, depression or PTSD to treatment.

“The pandemic has caused the need for psychedelic wellness to skyrocket,” says Matt Stang, CEO of Delic. “We are at a tipping point where the data and science regarding psychedelic therapies have become undeniable in the treatment of various serious conditions.”

As it stands, ketamine is legal in the United States for medical use. Ketamine is an FDA-approved anesthetic and can be prescribed for a myriad of ailments in a regulated setting by licensed clinicians. Psilocybin, like cannabis, is still considered a Schedule 1 drug in the eyes of the federal government. Therefore, its sale and use is illegal, despite some states and cities that have begun to decriminalize mushrooms. As of 2019, psilocybin has been decriminalized in Denver, Oregon and Santa Cruz. The state of California even has a measure on the 2022 ballot that would decriminalize psychedelic medicine in the state.

Psychedelic wellness companies like Delic are eager for this legal move. This echoes the beginning of the cannabis industry as we know it today, as states began decriminalizing ahead of legalization decades ago. the the largest clinical study to date confirms the effectiveness of psilocybin in treatment-resistant depression. Ketamine has even greater clinical research backing up its use for depression, anxiety, and PTSD.

Delic acquired Ketamine Wellness Centers (KWC) in November 2021. Today, Delic operates the largest chain of psychedelic mental health clinics in the United States, operating 12 ketamine wellness clinics. The company plans to open 15 additional clinics over the next 18 months. Stang says his team founded Delic to improve people’s lives and provide access to lifesaving medicines.

The Harris Poll to study found that 83% of Americans with anxiety, depression, or PTSD would be open to pursuing alternative treatments. Respondents said that if herbal medicines were found to be “more effective than prescription drugs with fewer side effects”, 66% would try ketamine, 62% would try psilocybin and 56% would try MDMA.

18% of respondents said that traditional pharmaceutical drugs did not improve their condition or even made it worse. The survey was conducted from December 6 to 8, 2021 among 2,037 adults aged 18 and over. Among them, the survey questioned 953 people suffering from anxiety, depression and/or PTSD.

“Delic Labs is developing analytical capabilities that will help form a complete picture of psychedelic medicine and ensure drug safety,” said Dr. Marcus Roggen, President and Chief Scientific Officer of Delic Labs.

“In the area of ​​medical developments, psilocybin and other herbal compounds show great promise, but also have their limitations,” says Dr. Roggen. “With our expertise in medicinal chemistry as a foundation, we will continue to explore these new psychedelic compounds and other drug candidates with the goal of adding them to this exciting field of medicine.”

The demographics of the group varied. Of those who participated, 48% identified themselves as men and 50.9% as women. With regard to age, we observed a wide variety of respondents with 28.4% aged between 18 and 34; 16.7% aged 35 to 44; 15.9% aged 45 to 54; 16.6% aged 55 to 64 and 21.5% aged over 65. When it comes to race, 61.8% identified as white, 16.5% identified as Hispanic, and 11.8% identified as black,” Stang says.

The survey is not exhaustive and respondents self-reported, which may leave room for potential bias. “This survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated,” Stang says.

“We are confident that the world will look back on this moment just before full global acceptance and notice how much more effective the treatment has become, in a very short time,” Stang says. “This promising family of new drugs has the potential to be more effective than traditional drugs with minimal side effects.”

In 2021, the company held its first Meet Delic Psychedelic Medicine Conference, one of the largest psychedelic wellness industry conferences in the world, which hosted 2,500 attendees. Tickets are on sale for his 2022 event taking place November 5-6, 2022 in Las Vegas, Nevada.

Delic is listed on the Canadian Securities Exchange (CSE: DELC), the OTC Market Group (OTCQB: DELCF) as well as Germany’s largest stock market called the Frankfurt Stock Exchange (ENG: 6X0).

Comments are closed.